文献速递消化系统肿瘤

雌激素联合孕激素与结直肠癌:妇女健康倡议随机临床试验的长期发现

Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial.
PubMed 文献 · J Clin Oncol · 2024-07-19

妇女健康倡议试验将16608名有子宫的绝经后女性随机分配至每日结合马雌激素0.625mg联合醋酸甲羟孕酮2.5mg组或安慰剂组,干预5.6年后干预组结直肠癌减少44%但淋巴结阳性更常见;累计随访24年、431例结直肠癌后,联合激素不再影响结直肠癌发病率(HR 0.95),结直肠癌死亡无统计学显著差异(HR 1.20)。

要点

  • 干预5.6年结束时干预组结直肠癌减少44%(43 vs 72,P=.003),但淋巴结阳性更常见(59.0% vs 29.4%,P=.003)。
  • 累计24年随访431例结直肠癌,联合激素不再影响发病率(215 vs 216,HR 0.95,95%CI 0.79-1.15)。
  • 结直肠癌死亡无统计学显著差异(87 vs 69,HR 1.20,95%CI 0.87-1.65,P=.26)。

核心结论

  • 约5年的结合马雌激素联合醋酸甲羟孕酮使用对结直肠癌结局无临床有意义的获益。

研究设计与样本

  • 妇女健康倡议随机临床试验,16608名有子宫的绝经后女性随机分配至每日结合马雌激素0.625mg联合醋酸甲羟孕酮2.5mg组或安慰剂组,干预5.6年后停止,累计随访24年。

主要发现

  • 干预5.6年结束时干预组结直肠癌减少44%(43 vs 72,P=.003),但淋巴结阳性更常见(59.0% vs 29.4%,P=.003)。
  • 累计24年随访共431例结直肠癌,联合激素不再影响结直肠癌发病率(215[0.15,年化率%] vs 216[0.15],HR 0.95[95%CI 0.79-1.15])。
  • 结直肠癌死亡无统计学显著差异(87[0.049] vs 69[0.041]例死亡,HR 1.20[95%CI 0.87-1.65],P=.26)。
  • 干预组阴道出血(6个月时54.1% vs 5.2%)和乳腺改变更常见。
  • 校正随机化后阴道出血和乳腺改变后,干预组肠道检查显著延迟(P=.005),可能促成诊断延迟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We report long-term colorectal cancer findings from the Women's Health Initiative trial where 16,608 postmenopausal women with a uterus were randomly assigned to daily conjugated equine estrogen (CEE) 0.625 mg, plus medroxyprogesterone acetate (MPA) 2.5 mg, or placebo. When intervention ended after 5.6 years, although there were 44% fewer colorectal cancers in the intervention group (43 v 72, P = .003), the cancers were more commonly lymph node-positive (59.0% v 29.4%, P = .003). Now after cumulative 24-year follow-up, with 431 colorectal cancers, CEE plus MPA no longer influenced colorectal cancer incidence (215 [0.15, annualized rate %] v 216 [0.15], hazard ratio [HR], 0.95 [95% CI, 0.79 to 1.15]). Although not statistically significant, there were more colorectal cancer deaths with CEE plus MPA (87 [0.049] v 69 [0.041] deaths, HR, 1.20 [95% CI, 0.87 to 1.65], P = .26). Vaginal bleeding (54.1% v 5.2% at 6 months) and breast changes were more frequent in the intervention group. After adjusting for postrandomization vaginal bleeding and breast changes, bowel examinations were significantly delayed in intervention group participants (P = .005), potentially contributing to diagnostic delay. Taken together, the findings suggest no clinically meaningful benefit for about 5 years of CEE plus MPA use on colorectal cancer outcome.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chlebowski RT, Aragaki AK, Pan K, et al. Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial. J Clin Oncol. 2024. PMID: 39028918. doi:10.1200/JCO.23.02092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。